Sign in
Taking peoplePhase 4

Plasma rich in growth factors for diabetic foot ulcers with poor leg circulation

Tests PRGF against usual care for healing foot ulcers in diabetic adults with artery disease.

Key facts

Who runs it
Biotechnology Institute IMASD
Where
Spain1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease
Status
Recruiting
Phase
Phase 4
People taking part
38 people, planned
Started
1 Nov 2025
Expected to end
30 May 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Topical application of Plasma Rich in Growth Factors (PRGF)
  • Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).
Record updated
11 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 or 2 diabetes who have a foot ulcer and poor blood flow in the legs (peripheral arterial disease). It compares PRGF, a treatment made from the patient's own blood, with conventional treatment.

Age
18 years and older
Sex
All sexes
Disease stage
One or more ulcers below the ankle bones, 1 to 25 cm2 in size. Infection of the wound no higher than 1 on the IDSA/IWGDF scale. Ulcers grade 3 or higher cannot join.
Earlier treatment
People cannot join if they are on other local treatment at the ulcer, on immunosuppressants, on monoclonal antibodies, or on regular NSAIDs for 3 months or more (acetylsalicylic acid is allowed).
Biomarker or test result
At least 2 of: no foot or leg pulses on exam, ankle pressure 50-90 mmHg, toe pressure 30-70 mmHg, ABI 0.5-0.9, FIBI 0.3-0.7, TcPO2 30-59 mmHg. Glycosylated hemoglobin must not be above 9%.

Main reasons for not taking part

  • Positive test for HCV, AfHBs, HIV-I/II or TP
  • Active infection throughout the body
  • Cancer or precancerous lesions in the treated area
  • Allergy to blood products or a known blood clotting disorder
  • Pregnancy, breastfeeding, or women who can become pregnant and do not use effective birth control

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Patients aged at least 18 years
  • Diagnosis of type 1 or 2 diabetes
  • Presence of one or more ulcers below the malleoli
  • Ulcer size ranging from 1 to 25 cm2
  • Peripheral Arterial Disease (PAD)
  • Meet at least 2 of the following crieria:
  • Absence of peripheral pulses at any level on physical examination of lower extremities
  • Ankle pressure of 50-90 mmHg
  • Finger pressure 30-70 mmHg
  • Ankle-branchial index (ABI) 0.5-0.9
  • Finger-arm index (FIBI) 0.3-0.7
  • Transcutaneous oxygen pressure (TcPO2) 30-59 mmHg
  • Degree of infection of the lesion on IDSA/IWGDF scale not greater than 1
  • Availability of observation during the study period
  • Properly completed patient informed consent

Who cannot take part

  • On active treatment with other local treatment at the site of treatment
  • On active treatment with immunosuppressants and/or other drugs contraindicating blood collection
  • Previous diagnosis of coagulopathies
  • Treatment with monoclonal antibodies
  • Positive markers for HCV, AfHBs, HIV-I/II or TP
  • Active systemic infection
  • History of cancerous or precancerous lesions in the area of intervention
  • History of allergy to blood derivatives
  • Diabetes mellitus with poor metabolic control (evidence of glycosylated hemoglobin >9%)
  • Pregnancy or women of chilbearig age not taking effective contraceptive measures. These methods are, according to recommendations of the Clinical Trial Facilitation Group (CTFG) Contraception Working Group (CTFG) (V1.1), the following Hormonal contraception associated with ovulation inhibition, intrauterine decide (IUD), intrauterine hormone-releasing system, bilateral tubal ligation, vasectomy partner, sexual abstinence
  • Ulcers grade 3 or higher
  • Regular and continuous treatment (≥ 3 months) with NSAIDs (with the exception of the use of acetylsalicilic acid)
  • Breastfeeding women
  • Any inabilities to participate in the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a randomized clinical trial that compares the effectiveness of Plasma Rich in Growth Factors (PRGF) with conventional treatment for healing foot ulcers in diabetic patients who also have peripheral arterial disease. The goal is to assess how well PRGF promotes healing over a six-month period.

The 2 groups in the trial

  • Topical application of Plasma Rich in Growth Factors (PRGF)Treatment being tested

    The Principal Investigator, or duly delegated qualified personnel, is responsible for the preparation using the KMU10-TPC Kit (BTI Biotechnology Institute, S.L.).

  • Conventional treatment with adequate offloading and metabolic control, +/- antibiotic).Existing treatment, for comparison

    Manufacturer: N/A

    Treatment: Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Clinical Trial, Controlled With Conventional Treatment to Evaluate the Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease
Plain-language title
Plasma rich in growth factors for diabetic foot ulcers with poor leg circulationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
11 September 2025